Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2)

Abstract

Introduction: Teneligliptin is an antidiabetic medication that has been approved for the management of type 2 diabetes mellitus (T2DM) in Japan, South Korea and India. It is one of the most commonly prescribed antihyperglycaemic agents. The aim of this study was to assess the effectiveness of teneligliptin in improving glycemic control amongst Indian patients with T2DM in a real-world setting. Methods: This was a retrospective observational study in which a predesigned structured proforma was used to collect information from hospital records of 18 medical centres across India. All participating centres were established primary care hospitals with adequate record keeping, a predetermined condition in the study design. Data were collected during the period of January 2019 to June 2019. Data extracted from patient records, including glycaemic parameters, concomitant drugs, drug dosage and duration, were collated. The effectiveness of teneligliptin was assessed by analyzing the mean change in glycosylated haemoglobin (HbA1c), fasting plasma glucose (FPG) and post-prandial plasma glucose (PPG) at 12 weeks after initiation of teneligliptin. Results: Data from 10,623 patients were available for analysis. The mean age of the enrolled patients was 51.86 ± 11.76 years. At 12 weeks after initiation of teneligliptin as monotherapy or add-on to other medications (combination therapy), the patients showed a signficant decrease from baseline in mean HbA1c, FPG and PPG. Mean HbA1c dropped from 8.66 ± 1.

A Real-World Observational Study on Diabetes Mellitus Patients Administering Dual Combination Therapy of Teneligliptin and Metformin to Evaluate Renal Function

“…The effectiveness of teneligliptin in the Indian population was first highlighted in the RWE study TREAT-INDIA (n = 4305) conducted by Ghosh et al, in which teneligliptin as a monotherapy and add-on therapy was shown to significantly reduce HbA1c (overall reduction by 1.37 ± 1.15%), FPG (overall reduction by 51.29 ± 35.41mg/dl) and PPG (overall reduction by 80.89 ± 54.27mg/dl). [12] Similar findings in the Indian population were reported by another real-world efficacy study conducted by Nashikkar et al [13].…”

An Observational Retrospective Real-World Study to Evaluate the Effect of Teneligliptin on Parameters of Renal Function, Glycemic Control, and Safety in Indian T2DM Patients with Chronic Kidney Disease (TOP RENAL)

“…The two large-scale RWE studies in the Indian population, TREAT-India 1 (N=4305 patients) and 2 (N= 10,623 patients), reflected the effectiveness of Teneligliptin in improving glycemic control in patients with T2DM when prescribed as monotherapy or as add-on to one or more antidiabetic drugs [17,18]. Teneligliptin also significantly reduced HbA1c (1.13% p < 0.0001) in patients with impaired renal function without worsening the eGFR [18]. Insight into differences in chemical structure, the binding mode to DPP4, and the lipophilicity of each DPP4 inhibitor suggests differences in their renoprotective effects as well.…”

Teneligliptin as an Adjuvant Therapy in Type 2 Diabetic Management: A Prospective Observational Study

“…According to Syngle et al, teneligliptin improves not only glycemic control but also pseudomotor function, peripheral and autonomic neuropathy and vascular inflammation in type 2 diabetes. [16][17][18][19] Panikar et al concluded that the DPP-4Is is effective in achieving desired glycemic goals even when used as a fourth drug in patients. 3 Saboo et al, in 2022, reported the addition of teneligliptin to the DM patients, whose blood glucose level is uncontrolled by Metformin monotherapy.…”